ParaPRO intros Natroba

Parasite treatment-focused pharmaceutical company ParaPRO is introducing Natroba (spinosad topical suspension, 0.9%) — the first new drug for scabies approved by the Food and Drug Administration in more than 30 years.

Earlier this year, the company received FDA approval of its supplemental New Drug Application for Natroba as a targeted topical treatment for scabies infestations in adult and pediatric patients age four years old and older. 

Natroba has been approved for the topical treatment of head lice infestations since 2011 and is currently the most frequently prescribed treatment option, according to the company.

"There are known limitations with existing scabicides, and for more than 30 years, practitioners have had to rely on the same active pharmaceutical ingredients to treat scabies," said Bill Culpepper III, president of ParaPRO. "We are pleased to offer healthcare providers and their patients the first pharmacological advancement in scabies treatment in decades. Natroba is a targeted topical therapy that was shown to be highly effective and well-tolerated in the treatment of scabies following one application of the study drug."